Document is current
Any future updates will be listed below
-
Authors
Pemberton, Hugh G. http://orcid.org/0000-0001-8419-6423
Collij, Lyduine E.
Heeman, Fiona http://orcid.org/0000-0001-7769-8329
Bollack, Ariane
Shekari, Mahnaz
Salvadó, Gemma http://orcid.org/0000-0002-5210-9230
Alves, Isadora Lopes
Garcia, David Vallez http://orcid.org/0000-0003-3308-3167
Battle, Mark http://orcid.org/0000-0002-6190-6389
Buckley, Christopher
Stephens, Andrew W. http://orcid.org/0000-0001-5052-6586
Bullich, Santiago http://orcid.org/0000-0001-5669-269X
Garibotto, Valentina
Barkhof, Frederik http://orcid.org/0000-0003-3543-3706
Gispert, Juan Domingo
Farrar, Gill
,
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115952)
- License Information
-
More Information
Article History
Received: 6 December 2021
Accepted: 25 March 2022
First Online: 7 April 2022
Declarations
:
: Not applicable for this review.
: Not applicable for this review.
: Not applicable for this review.
: HP, GF, MB, and CB are all employees of GE Healthcare. SB and AS are employees of Life Molecular Imaging GmbH. VG has received funding from the Swiss National Science Foundation (project n. 185028, 188355, and 169876), the Velux Foundation, the Schmidheiny Foundation, and research/teaching support through her institution from Siemens Healthineers, GE Healthcare, Roche, Merck, Cerveau Technologies, and Life Molecular Imaging. FB is a steering committee and iDMC member of studies by Biogen, Merck, Roche, and EISAI. He is a consultant to Roche, Biogen, Merck, IXICO, Jansen, and Combinostics. He has research agreements with Novartis, Merck, Biogen, GE, and Roche and is co-founder of Queen Square Analytics Ltd. His research is sponsored by the NIHR-UCLH Biomedical Research Centre, UK MS Society, MAGNIMS-ECTRIMS, EC-H2020, EC-JU (IMI), and EPSRC.
